Pearl IRB,LLC and Trafalgar Ethics Board, Inc. announce a partnership to provide one stop shop service for central IRB (Institutional Review Board) services for clients. The trend for research sponsors to conduct multi-center global clinical trials continues to grow, with the United States and Canada accounting for 60.5%1 of sponsored clinical trials in 2010. Pearl IRB, based in the United States in Indianapolis and Trafalgar Ethics Board headquartered in the Toronto area in Canada, join forces to deliver integrated United States–Canada study reviews.
“We have partnered to serve the needs of our clients in a more streamlined fashion,” shares Ali Thompson, Director of Trafalgar Ethics Board. “Both our Canadian clients and US based sponsors are demanding higher quality and increased efficiencies in the global regulatory oversight of their clinical trials. By working together to provide United States–Canada IRB reviews, we eliminate much duplication and help streamline work for our clients.”
Clinical trials are often delayed for many reasons including contract negotiations, budgeting issues, and IRB reviews. “We strive to decrease site review times by integrating our processes to provide parallel US and Canadian site reviews, states Diana Caldwell, President and CEO of Pearl IRB. “Additionally, we will partner to offer additional services that are of high value to our clients including medical writing, GCP/ICH assistance, and site training all of which reach across Canada and the US now.”
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Gilead Shares Final Data from Phase III MYR301 Trial of Bulevirtide in Chronic Hepatitis Delta Virus
May 7th 2025Long-term results from the study show 90% of patients with chronic HDV who achieved undetectable HDV RNA at 96 weeks of treatment remained undetectable for nearly 2 years post-treatment.